Office of the President continues to perform the duties of President and CEO
REDWOOD CITY, Calif., Nov. 27, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that Chairman, President and Chief Executive Officer Paul J. Hastings will resume his Chairman of the Board responsibilities, effective December 4, 2017.
The Office of the President, comprised of Executive Vice President, Research and Development, John Lewicki, and Executive Vice President and Chief Financial Officer, Sunil Patel, will continue to perform the duties of President and CEO. The Office of the President will continue to report to a special committee of the Board of Directors composed of Deepa Pakianathan, Jack Lasersohn, Rick Winningham and Perry Karsen.
Read More: http://www.oncomed.com/invest/releasedetail.cfm?ReleaseID=1049868
OncoMed Announces Chairman, President and Chief Executive Officer Paul J. Hastings to Resume Chairman Responsibilities
Outset Medical Expands Senior Leadership Team by Adding Chief Operating Officer and Commercial Strategy VP
Via: Yahoo! Finance
Outset Medical, a commercial-stage company delivering new technology into the $13 billion global dialysis market, today announced the appointment of two new executives: Martin Vazquez, who joins the company as Chief Operating Officer, and Chad Hoskins as Vice President, Commercial and Corporate Strategy.
Q3 Cash Balance of $113.6M — Cash through Q3 2019
Diabetes is one of the most pervasive and expensive chronic diseases: It affects an estimated 30.3 million people in the United States and costs a staggering $245 billion per year to treat. In addition there are 84.1 million adults in the United States with high blood sugar levels in danger of developing type 2 diabetes. It is widely acknowledged that the most effective method of treating these prediabetics so they don’t become full-fledged diabetics is diabetes prevention programs (DPPs) that follow a protocol validated by the Centers for Disease Control and Prevention (CDC). But the challenge has been to get people to enroll in them in the first place and stick with them if they do.
Via: Union News Daily
SUMMIT, NJ — A new preventive procedure that is more accessible to seniors is now offered at Atlantic Health System’s Overlook Medical Center, helping patients to reduce the risk of stroke.
SUMMIT, NJ — Atlantic Health System’s Overlook Medical Center is the first hospital in New Jersey to offer an innovative new treatment for patients at risk for stroke due to blockages in the neck arteries, a condition known as carotid artery disease.
If we hope to be successful in a rapidly changing health care environment, dialysis providers can't afford to maintain the status quo. "Successful" doesn't just refer to financial stability; it also means providing good quality care for our patients.
Silk Road Medical Appoints World Class Stroke Prevention Champion to Serve as Vice President, Medical Affairs and Professional Education
Via: Business Insider
SUNNYVALE, Calif., Oct. 11, 2017 /PRNewswire/ -- Silk Road Medical, Inc., a company dedicated to preventing the devastating burden of stroke through surgical innovation, announces the appointment of Tammy Leitsinger to the position of Vice President, Medial Affairs and Professional Education. In this new role, Tammy will further develop and refine global, peer-to-peer TCAR training pathways and innovative educational programs.
TCAR is a new procedure, only available in 50 hospitals across the United States, that helps prevent strokes in high-risk patients. Dr. Brad Thomas is a vascular surgeon with Surgical Care Associates at Baptist Health Louisville.
With over $100 million in capital raised from well-heeled investors including Warburg Pincus, the Vertical Group, Norwest Venture Partners, and the Janus Funds, Silk Road Medical is built for the long haul.